30 closest matches · ranked by relevance
Infectious Mononucleosis
Primary: Number of Participants With Improvement in Clinical Symptoms and Reductions in Viral Burden From Baseline — 12; 11 participants
Epstein-Barr Virus-Associated Lymphoma · Lymphoproliferative Disorders
Primary: Number (Proportion) of Participants With Adverse Events (AEs) — 7; 5; 4; 4 Participants
EBV-induced Lymphomas · EBV-associated Malignancies · Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
Primary: Objective Response Rate (ORR) — 68.0; 50.0; 16.0; 14.3 Percentage of participants
Relapsed or Refractory EBV-and CD30-positive Lymphomas
Primary: To Evaluate the Overall Response Rate (ORR) of Brentuximab Vedotin in EBV- and CD30-positive Lymphomas — 12 Participants
Post-transplant Lymphoproliferative Disease · Solid Organ Transplant · Stem Cell Transplant (Bone Marrow Transplant)
Primary: Overall Response Rate — 3 Participants
BK Virus (BKV) Viremia
Primary: Incidence of BKV Viremia in the Study Population of Screened Renal or Renal-pancreas Transplant Subjects — 58 Participants
Nasopharyngeal Carcinoma
Primary: Best Overall Response Rate (ORR) — 0.0 percentage of participants
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
CMV DNAemia Pre-engraftment
Primary: Time to Engraftment (Days) Stratified by CMV DNaemia Occurring Before or After Neutrophil's Engraftment — 17; 19 days
Viral Infection
Primary: Number of Participants With a DLT — 0; 0; 0; 3 Participants
EBV-induced Lymphomas · EBV-associated Malignancies · Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
Primary: Objective Response Rate (ORR) — 63.6; 50.0; 0; 43.5 Percentage of participants
Hodgkin's Disease · Leukemia · Myelodysplastic Syndrome
Primary: Safety of Rituximab Prophylaxis — 23 participants
HIV Infections · Hepatitis B
Primary: Hepatitis B Virus (HBV) DNA — 2.4; 0.8 log 10 IU/ml
Hepatitis B · Chronic Hepatitis B
Primary: Change in Mean Hepatitis B Virus (HBV) DNA Levels — 10.290; 9.721; 3.669; 3.194 log10 copies/mL
Infection
Primary: Number of Patients Where a Suitable VST Line Could be Found — 80 Participants
EBV-Related Post-Transplant Lymphoproliferative Disorder · Monomorphic Post-Transplant Lymphoproliferative Disorder · Polymorphic Post-Transplant Lymphoproliferative Disorder
Primary: Percentage of Patients Assigned to Arm Latent Membrane Protein-specific T-cells (LMP-TC) With Successful LMP-specific T Cell Product Match, Were Treated Within Two Weeks…
Transplantation Infection · Epstein-Barr Virus Infections · Cytomegalovirus Infections
Primary: Compare Incidence, Duration and Magnitude of CMV and EBV Viremia in Kidney Transplant Recipients Receiving valA vs. valG. — 16; 20; 8; 4 Participants
Carcinoma, Hepatocellular · Chronic Hepatitis B
Primary: 1,3,5 Year-Disease Free Survival (or Recurrence Free Survival) — 11; 13; 25; 34 participants
Tick Borne Encephalitis
Primary: Outcome of the Neutralization Test (Number of Subjects With Antibody Response Measured by Neutralization Assay) — 6; 14 Participants — p=<0.001
Chronic Hepatitis B
Primary: Change in HBsAg Levels From Baseline to 2 Years — -0.27 log IU/ml — p=<0.05
HIV · Salivary Gland Disease · Benign Lymphoepithelial Lesion
Primary: BK Viral Status in Saliva at Week 4 — 3; 6; 5; 1 Participants
Chronic Hepatitis B
Primary: Percentage of Participants Who Achieved a Virologic Response at Week 24 — 92.86; 67.19 Percentage of participants — p=0.0006
Lymphoma, T-Cell, Cutaneous · Sézary Syndrome
Primary: Number of Participants With Viral Sequences Present in Malignant T Cells of Patients With Sézary Syndrome — 6 Participants
Double-stranded DNA Virus
Primary: Number of Subjects Who Had a Sustained and Significant Reduction in Plasma Viral Load of Primary dsDNA Virus — 15; 18; 39; 13 Participants
Adenovirus Infection · BK Virus Infection · Cytomegalovirus Infections
Primary: Number of Participants Experiencing Clinically Significant Infections or Episodes of End-organ Disease — 3 Participants
Adenovirus Infection
Primary: Number of Participants With All-Cause Mortality — 9; 27; 8 Participants
Cytomegalovirus Infections
Primary: a) CMV Viral Load — 100; 97.6; 86.36; NA percentage of agreement
Hepatitis B
Primary: Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations as Measured by ELISA Equal to or Above Cut-off Value — 266 Participants
HSV · Herpes Labialis
Primary: Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline — 10.073; 11.380; 10.711; 11.431 q-RT-PCR crossing threshold cycle (Ct)
EBV Viremia · CMV Viremia
Primary: Incidence of EBV or CMV Related Disease in Transplant Recipient — 2; 0 participants